MS Speaks

From FiercePharma (April 21, 2021)--"Roche, playing defense against Novartis' Kesimpta, touts Ocrevus benefits in treating MS early":




https://www.fiercepharma.com/pharma/roche-playing-against-novartis-kesimpta-touts-ocrevus-benefits-treating-ms-early


Although this article is over a year old, it contains an interesting bit of data that surprised me:

About 80% of patients adhered to twice-yearly dosing of Ocrevus after their second year of treatment. That was compared with 54% for other IV drugs, 35% for intramuscular and under-the-skin injectables, and 55% for orals.[/size]

[size=78%]Only 35% of the MS patients on the intramuscular and under-the-skin injectables stay on them after the second year.  Does this dismal adherence indicate a vote of no-confidence in those drugs, or is it more that people find doing the injections to be difficult?[/size]